Skip to Main Content
Esther Golnabi, Pharm.D.

Esther Golnabi, Pharm.D.

Titles and Appointments

Clinical Pharmacist Specialist

Assistant Professor

School
Medical School
Department
Pharmacy Administration | Internal Medicine
  • Biography

    Esther Golnabi, PharmD, BCIDP, is an infectious diseases and antimicrobial stewardship pharmacist at UT Southwestern Medical Center, where she serves as the lead outpatient parenteral antimicrobial therapy (OPAT) and ambulatory antimicrobial stewardship pharmacist.

    Dr. Golnabi earned her pharmacy degree from Texas Tech University Health Sciences Center. She completed a PGY-1 pharmacy residency at UT Southwestern Medical Center, followed by a PGY-2 infectious diseases pharmacy residency at The Johns Hopkins Hospital in Baltimore, MD.

    With a focused interest in OPAT and ambulatory antimicrobial stewardship, Dr. Golnabi is committed to optimizing the use of antimicrobial agents and improving patient outcomes across a variety of healthcare settings. Her professional and research interests are centered on developing and implementing multidisciplinary stewardship initiatives designed to enhance antimicrobial therapies during transitions of care and in outpatient settings, including emergency departments. She emphasizes clinical efficacy, patient safety, and cost-effectiveness in her work. Additionally, Dr. Golnabi is passionate about educating pharmacy residents and students in the areas of infectious diseases, antimicrobial stewardship, and research project development.

    Beyond her work at UT Southwestern, she is an active member of the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy Infectious Diseases Practice Research Network (ID PRN), and the Vizient Pharmacy Antimicrobial Stewardship Committee.

  • Research Interest
    • Antimicrobial stewardship initiatives in transitions of care settings
    • Early transition to oral antibiotics in deep-seated infections
    • Factors associated with successful outcome of outpatient parenteral antimicrobial therapy (OPAT)
    • Optimization of durations of antibiotic therapy in common infections
  • Publications

    Star Featured Publications

    Featured Featured Featured
    Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.
    Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM, Lancet Infect Dis 2024 Dec
    Antimicrobial Stewardship Practices in Outpatient Parenteral Antimicrobial Therapy Programs in the United States.
    Azimi SF, Golnabi E, Mynatt RP, Burgess D, Logan A, Wrenn RH, Parisi Mercado M, Boeser K, Plauche A, Sexton ME, Walraven C, Open Forum Infect Dis 2024 Jul 11 7 ofae347
    A case-control study evaluating the unnecessary use of intravenous broad-spectrum antibiotics in presumed sepsis and septic-shock patients in the emergency department.
    Bae EY, Smith TT, Monogue ML, Antimicrob Steward Healthc Epidemiol 2022 2 1 e193
    Development and implementation of a short duration antibiotic therapy algorithm for uncomplicated gram-negative bloodstream infections.
    Bae EY, Dzintars K, Bernice F, Tamma PD, Cosgrove SE, Avdic E, Infect Control Hosp Epidemiol 2021 Sep 42 9 1136-1138
    Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
    Golnabi EY, Sanders JM, Johns ML, Lin K, Ortwine JK, Wei W, Mang NS, Cutrell JB, Curr Infect Dis Rep 2021 23 12 28